JPRN-UMIN000018889已完成未知
a study on SDI-DLB concerning to diagnose DLB and assess benefit for Donepezil : Study 1 - SDI-DLB: diagnose DLB and assess benefit for Donepezil(Study 1)
Promedico Co., Ltd.0 个研究点目标入组 150 人开始时间: 2015年9月3日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 60years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)dozed antidementia drugs except Donepezil within 12 weeks before informed consent 2)bed ridden 3)with severe impairment of visual acuity, auditory sensor and/or communication 4)with neurological degenerative disease except for DLBV criteria, schizophrenia, bipolar disorder and major depression 5)with delirium due to abuse of alcohol, drugs, metabolic toxicity and inflammation
研究者
相似试验
已完成
不适用
a study on SDI-DLB concerning to diagnose DLB and assess benefit for Donepezil : Study 2DLBJPRN-UMIN000018813Promedico Co., Ltd.30
已完成
不适用
Clinical Application of SDL-PDTL57.0Actinic keratosisDRKS00020427MVZ Dermatologisches Zentrum Bonn GmbH12
已完成
不适用
Elucidating the therapeutic mechanism of DBSObsessive-compulsive disorderNL-OMON21978Board of Directors, Academic Medical Center, Amsterdam11
已完成
不适用
Elucidating the therapeutic mechanism of DBS by simultaneously stimulating and recording from the target brain region.10037173anxiety disorderObsessive-compulsive disorderNL-OMON50295Academisch Medisch Centrum11
招募中
1 期
Application and evaluation of Syndrome differentiation Xerox in chronic disease management of patients with advanced lung cancerung cancerITMCTR2100004467Dongfang Hospital of Beijing University of Chinese Medicine